Reflections on MicroRNAs in chronic pulmonary disease: Looking into the miR-ror and crystal ball

Inflammation and Allergy - Drug Targets

Volumn 12, Issue 2, 2013, Pages 88-98

  Karras, James G ^a   Sun, Guizhen ^a   Tay, Jia ^a   Jackson, Aimee L ^b  

^a REGULUS THERAPEUTICS   (United States)

^b Jackson BioConsulting   (United States)

Author keywords

Inhaled anti miRS; MicroRNA; Pulmonary inflammation; Regulatory gene networks

Indexed keywords

ADENOSINE A1 RECEPTOR; AIR 645; ALN RSV 01; ANTISENSE OLIGONUCLEOTIDE; ASM 8; CELL SURFACE MARKER; CORTICOSTEROID; DEXAMETHASONE; INTERLEUKIN 12P35; INTERLEUKIN 13; MICRORNA; MICRORNA 126; MICRORNA 145; MICRORNA 155; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; SMAD7 PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ALLERGIC RHINITIS; ARTICLE; ASTHMA; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; CLINICAL TRIAL (TOPIC); CYSTIC FIBROSIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SPUTUM LEVEL; ENTERITIS; EPIGENETICS; FIBROSING ALVEOLITIS; GENE EXPRESSION; HUMAN; MASS SPECTROMETRY; MULTIPLE SCLEROSIS; NONHUMAN; PHARMACOKINETICS; PNEUMONIA; PULMONARY ARTERY OCCLUSION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RHEUMATOID ARTHRITIS; SEVERE PERSISTENT ASTHMA; SINGLE DRUG DOSE; VIRUS INFECTION;

ANIMALS; CHRONIC DISEASE; HUMANS; LUNG DISEASES; MICRORNAS;

EID: 84876704045     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871528111312020003     Document Type: Article

References (56)

1. Lennox, K.A.; Behlke, M.A. Chemical modification and design of anti-miR oligonucleotides. Gene Ther., 2011, 18, 1111-1120.
2. nd ed.; Crooke, S.T., Ed.; Taylor & Francis, CRC Press: London, UK, 2007; pp. 143-182.
3. Gauvreau, G.; Pageau, R.; Seguin, R.; Carballo, D.; Gauthier, J.; D'Anjou, H.; Campbell, H.; Watson, R.; Mistry, M.; Parry-Billings, M.; Killian, K.J.; Renzi, P.M. Dose-response effects of TPI ASM8 in asthmatics after allergen. Allergy, 2011, 66, 1242-1248.
4. Hodges, M.; Castelloe, E.; Chen, A.; Geary, R.; Karras, J.; Larouche, R.; Shapiro, D.; Yeung, B.; Yu, R.; Gregory, S. A phase 1 multiple dose safety and pharmacokinetics study of AIR645, an inhaled IL-4Ra 2'-O-methoxyethyl gapmer oligonucleotide, A1800, Karras et al. Vienna, Austria, 12-15 September 2009; European Respiratory Society Annual Congress Proceedings.
5. Ball, H.A.; Sandrasagra, A.; Tang, L.; Van Scott, M.; Wild, J.; Nyce, J.W. Clinical potential of respirable antisense oligonucleotides (RASONS) in asthma. Am. J. Pharmacogenomics, 2003, 3, 97-106.
6. Ball, H.A.; Van Scott, M.R.; Robinson, C.B. Sense and antisense: therapeutic potential of oligonucleotides and interference RNA in asthma and allergic disorders. Clin. Rev. Allergy & Immunol., 2004, 27, 207-218.
7. Allam, M.; Renzi, P.M. Inhibition of GM-CSF/IL-3/IL-5 signaling by antisense oligodeoxynucleotides targeting the common beta chain of their receptors. Antisense Nucleic Acid Drug Dev., 2001, 11, 289-300.
8. DeVincenzo, J.; Cehelsky, J.E.; Alvarez, R.; Elbashir, S.; Harborth, J.; Toudjarska, I.; Nechev, L.; Murugaiah, V.; Van Vliet, A.; Vaishnaw, A.K.; Meyers, R. Evaluation of safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res., 2008, 77, 225-231.
9. DeVincenzo, J.; Lambkin-Williams, R.; Wilkinson, T.; Cehelsky, J.; Nochur, S.; Walsh, E.; Meyers, R.; Gollob, J.; Vaishnaw, A. A randomized, double-blind, placebo-controlled study of an RNAi- based therapy directed against respiratory syncytial virus. Proc. Natl. Acad. Sci. U.S.A., 2010, 107, 8800-8805.
10. Zamora, M.R.; Budev, M.; Rolfe, M.; Gottlieb, J.; Humar, A.; DeVincenzo, J.; Vaishnaw, A.; Cehelsky, J.; Albert, G.; Nochur, S.; Gollob, J.A.; Glanville, A.R. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am. J. Respir. Crit. Care Med., 2011, 183, 531-538.
11. Zabecor Inc. Home Page. www.zabecor.com [Accessed October 2012].
12. Karras, J.; Geary, R.; Gregory, S. Inhaled antisense oligonucleotide therapies: inspiration and progress. Drug Disc. Today: Therap. Strat., 2006, 3, 335-341.
13. Seguin, R.M.; Ferrari, N. Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease. Expert Opin. Investig. Drugs, 2009, 18, 1505-1517.
14. Gauvreau, G.; Boulet, L.P.; Cockcroft, D.W.; Baatjes, A.; Cote, J.; Deschesnes, F.; Davis, B.; Strinich, T.; Howie, K.; Duong, M.; Watson, R.M.; Renzi, P.M.; O'Byrne, P.M. Antisense therapy against CCR3 and the common beta chain attenuates allergen- induced eosinophilic responses. Am. J. Respir. Crit. Care Med., 2008, 177, 952-958.
15. Rayner, K.J.; Esau, C.C.; Hussain, F.N.; McDaniel, A.L.; Marshall, S.M.; van Gils, J.M.; Ray, T.D.; Sheedy, F.J.; Goedeke, L.; Liu, X.; Khatsenko, O.G.; Kaimal, V.; Lees, C.J.; Fernandez-Hernando, C.; Fisher, E.A.; Temel, R.E.; Moore, K.J. Inhibition of miR-33-a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature, 2011, 478, 404-409.
16. Ho, B-C.; Yu S-L.; Chen, J.J.W.; Chang, S-Y.; Yan, B-S.; Hong, Q-S.; Singh, S.; Kao, C-L.; Chen, H-Y.; Su, K-Y.; Li, K-C.; Cheng, C-L.; Cheng, H-W.; Lee, J-Y.; Lee, C-N.; Yang, P-C. Enterovirus- induced miR-141 contributes to shutoff of host protein translation by targeting the translation initiation factor eIF4E. Cell Host & Microbe., 2011, 9, 58-69.
17. Judson, R.L.; Babiarz, J.; Venere, M.; Blelloch, R. Embryonic stem cell specific microRNAs promote induced pluripotency. Nat. Biotechnol., 2009, 27(5), 459-461.
18. Bhattacharyya, S.; Balakathiresan, N.S.; Dalgard, C.; Gutti, U.;Armistead, D.; Jozwik, C.; Srivastava, M.; Pollard, H.B.; Biswas, R. Elevated miR-155 promotes inflammation in cystic fibrosis by driving hyper-expression of interleukin-8. J. Biol. Chem., 2011, 286, 11604-11615.
19. Gillen, A.E.; Gosalia, N.; Leir, S-H.; Harris, A. MicroRNA regulation of expression of the cystic fibrosis transmembrane conductance regulator gene. Biochem. J., 2011, 438, 25-32.
20. Liu, G.; Friggeri, A.; Yang, Y.; Milosevic, J.; Ding, Q.; Thannickal, V.J.; Kaminski, N.; Abraham, E. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J. Exp. Med., 2010, 207, 1589-1597.
21. Shaoqing, Y.; Ruxin, Z.; Guojun, L.; Zhiqiang, Y.; Hua, H.; Shudong, Y.; Jie, Z. Microarray analysis of differentially expressed microRNAs in allergic rhinitis. Am. J. Rhinol. Allergy, [Online] 2011, 25(6), 242-246. Ingentaconnect. http://dx.doi.org/10.2500/ajra.2011.25.3682 [Accessed 18th March 2013].
22. Yang, M.; Yao, Y.; Eades, G.; Zhang, Y.; Zhou, Q. miR-28 regulates Nrf2 expression through a Keap-1-independent mechanism. Breast Cancer Res. Treat., 2011, 129, 983-991.
23. Oglesby, I.K.; McElvaney, N.G.; Greene, C.M. MicroRNAs in inflammatory lung disease - master regulators or target practice? Resp. Res., 2010, 11, 148-160.
24. Xu, W.; Hui, C.; Yu, S.S.B.; Jing, C.; Chan, H.C. MicroRNAs and cystic fibrosis - an epigenetic perspective. Cell Biol. Intl., 2011, 35, 463-466.
25. Tomankova, T.; Petrek, M.; Kriegova, E. Involvement of microRNAs in physiological and pathological processes in the lung. Resp. Res., 2010, 11, 159-168.
26. Ariel, D.; Upadhyay, D. The role and regulation of microRNAs in asthma. Curr. Opin. Allergy Clin. Immunol., 2012, 12, 49-52.
27. Pagdin, T.; Lavender, P. MicroRNAs in lung diseases. Thorax, 2012, 67, 183-184.
28. Polikepahad, S.; Knight, J.M.; Naghavi, A.O.; Opit, T.; Creighton, C.J.; Shaw, C.; Benham, A.L.; Kim, J.; Soibam, B.; Harris, R.A.; Coarfa, C.; Zariff, A.; Milosavljevic, A.; Batts, L.M.; Kheradmand, F.; Gunaratne, P.H.; Corry, D.B. Pro-inflammatory role for let-7 microRNAs in experimental asthma. J. Biol. Chem., 2010, 285, 30139-30149.
29. Mattes, J.; Collison, A.; Plank, M.; Phipps, S.; Foster, P.S. Antagonism of microRNA-126 suppresses the effector function of Th2 cells and the development of allergic airways disease. Proc. Natl. Acad. Sci. U.S.A., 2009, 106, 18704-18709.
30. Collison, A.; Mattes, J. Plank M Biol, D Foster P.S. Inhibition of house dust mite-induced allergic airways disease by antagonism of microRNA-145 is comparable to glucocorticoid treatment. J. Allergy Clin. Immunol., 2011, 128, 160-167.
31. Lu, T.X.; Hartner, J.; Lim, E.J.; Fabry, V.; Mingler, M.K.; Cole, E.T.; Orkin, S.H.; Aronow, B.J.; Rothenberg, M.E. MicroRNA-21 limits in vivo immune response-mediated activation of the IL- 12/IFN-gamma pathway, Th1 polarization, and the severity of delayed-type hypersensitivity. J. Immunol., 2011, 187, 3362-3373.
32. Gregory, L.G.; Causton, B.; Murdoch, J.R.; Mathie, S.A.; O'Donnell, V.; Thomas, C.P.; Priest, F.M.; Quint, D.J. Lloyd C.M. Inhaled house dust mite induces pulmonary T helper 2 cytokine production. Clin. & Expl. Allergy, 2009, 39, 1597-1610.
33. Stanczyk, J.; Pedrioli, D.M.; Brentano, F.; Sanchez-Pernaute, O.; Kolling, C.; Gay, R.E.; Detmar, M.; Gay, S.; Kyburz, D. Altered expression of microRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arth. Rheum., 2008, 58, 1001-1009.
34. Kurowska-Stolarska, M.; Alivernini, S.; Ballantine, L.E.; Asquith, D.L.; Millar, N.L.; Gilchrist, D.S.; Reilly, J.; Ierna, M.; Fraser, A.R.; Stolarski, B.; McSharry, C.; Hueber, A.J.; Baxter, D.; Hunter, J.; Gay, S.; Liew, F.Y.; McInnes, I.B. MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc. Natl. Acad. Sci. U.S.A., 2011, 108, 11193-11198.
35. O'Connell, R.M.; Taganov, K.D.; Boldin, M.P.; Cheng, G.; Baltimore, D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc. Natl. Acad. Sci. U.S.A., 2007, 104, 1604-1609.
36. Mohamed, J.S.; Lopez, M.A.; Boriek, A.M. Mechanical stretch up-regulates microRNA-126 and induces human airway smooth muscle hypertrophy by suppressing glycogen synthase kinase-3b. J. Biol. Chem., 2010, 285, 29336-29347.
37. Chiba, Y.; Tanabe, M.; Goto, K.; Sakai, H.; Misawa, M. Down-regulation of miR-133a contributes to up-regulation of RhoA in bronchial smooth muscle cells. Am. J. Respir. Crit. Care Med., 2009, 180, 713-719.
38. Polikepahad, S.; El-Daye, J.; Naghavi, A.; Miller, J.; Gunaratne, P.; Corry, D.B. Lung RNA profiling suggests an essential role for microRNAs in regulating allergic lung disease. Proceedings of the American Association for Immunology, Effector Cell Processes, J. Immunol., 2007, 178, 91.9 (S161).
39. Woodruff, P. Insights from gene and miRNA expression studies in asthma. Proceedings of the American Thoracic Society Annual Meeting Scientific Symposium, Beyond Genome-wide Association Studies: Genomic and Epigenetic Approaches to Understanding Lung Diseases (C12), Denver, CO, 13-18 May 2011.
40. Izzotti, A.; Calin, G.A.; Arrigo, P.; Steele, V.E.; Croce, C.M.; De Flora, S. Downregulation of microRNA expression in the lungs of rats exposed to cigarette smoke. FASEB J., 2009, 23, 806-812.
41. Schembri, F.; Sridhar, S.; Perdomo, C.; Gustafson, A.M.; Zhang, X.; Ergun, A.; Lu, J.; Liu, G.; Zhang, X.; Bowers, J.; Vaziri, C.; Ott, K.; Sensigner, K.; Collins, J.J.; Brody, J.S.; Getts, R.; Lenburg, M.E.; Spira, A. MicroRNAs as modulators of smoking-induced gene expression changes in human airway epithelium. Proc. Natl. Acad. Sci. U.S.A., 2009, 106, 2319-2324.
42. Van Pottelberge, G.R.; Mestdagh, P.; Bracke, K.R.; Thas, O.; van Durme, Y.M.T.A.; Joos, G.F.; Vandesompele, J.; Brusselle, G.G. MicroRNA expression in induced sputum of smokers and patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2010, 183, 898-906.
43. Ezzie, M.E.; Crawford, M.; Cho, J-H.; Orellana, R.; Zhang, S.; Gelinas, R.; Batte, K.; Yu, L.; Nuovo, G.; Galas, D.; Diaz, P.; Wang, K.; Nana-Sinkam, S.P. Gene expression networks in COPD: microRNA and mRNA regulation. Thorax, 2012, 67, 122-131.
44. Sato, T.; Liu, X.; Nelson, A.; Nakanishi, M.; Kanaji, N.; Wang, X.; Kim, M.; Li, Y.; Sun, J.; Michalski, J.; Patil, A.; Basma, H.; Holz, O.; Magnussen, H.; Rennard, S.I. Reduced miR-146a increases prostaglandin E2 in chronic obstructive pulmonary disease fibroblasts. Am. J. Respir. Crit. Care Med., 2010, 182, 1020-1029.
45. Boldin, M.P.; Taganov, K.D.; Rao, D.S.; Yang, L.; Zhao, J.L.; Kalwani, M.; Garcia-Flores, Y.; Luong, M.; Devrekanli, A.; Xu, J. Sun, G.Tay, J. Linsley P.S. Baltimore D. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J. Exp. Med., 2011, 208, 1189-1201.
46. Seemungal, T.; Harper-Owen, R.; Bhowmik, A.; Moric, I.; Sanderson, G.; Message, S.; MacCallum, P.; Meade, T.W.; Jeffries, D.J.; Johnston, S.L.; Wedzicha, J.A. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2001, 164, 1618-1623.
47. Ito, K.; Ito, M.; Elliott, W.M.; Cosio, B.; Caramori, G.; Kon, O.M.; Barczyk, A.; Hayashi, S.; Adcock, I.M.; Hogg, J.C.; Barnes, P.J. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N. Engl. J. Med., 2005, 352, 1967-1976.
48. Mizuno, S.; Yasuo, M.; Bogaard, H.J.; Kraskauskas, D.; Natarajan, R.; Voelkel, N.F. Inhibition of histone deacetylase causes emphysema. Am. J. Physiol. Lung Cell. Mol. Physiol., 2011, 300(3), L402-413.
49. Mizuno, S.; Bogaard, H.J.; Gomez-Arroyo, J.; Alhussaini, A.; Kraskauskas, D.; Cool, C.D.; Voelkel, N.F. MicroRNA-199a-5p is associated with hypoxia inducible factor-1a expression in the lung from COPD patients. Chest, 2012, 142(3), 663-672.
50. Oglesby, I.K.; Bray, I.M.; Chotirmall, S.H.; Stallings, R.L.; O'Neill, S.J.; McElvaney, N.G.; Greene, C.M. miR-126 is downregulated in cystic fibrosis airway epithelial cells and regulates TOM1 expression. J. Immunol., 2010, 184, 1702-1709.
51. Ramsey, B.W.; Davies, J.; McElvaney, N.G.; Tullis, E.; Bell, S.C.; Drevinek, P.; Griese, M.; McKone, E.F.; Wainwright, C.E.; Konstan, M.W.; Moss, R.; Ratjen, F.; Sermet-Gaudelus, I.; Rowe, S.M.; Dong, Q.; Rodriguez, S.; Yen, K.; Ordonez, C.; Elborn, J.S.; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med., 2011, 365, 1663-1672.
52. Pandit, K.V.; Corcoran, D.; Yousef, H.; Yarlagadda, M.; Tzouvelekis, A.; Gibson, K.F.; Konishi, K.; Yousem, S.A.; Singh, M.; Handley, D.; Richards, T.; Selman, M.; Watkins, S.C.; Pardo, A.; Ben-Yehudah, A.; Bouros, D.; Eickelberg, O.; Ray, P.; Benos, P.V.; Kaminski, N. Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med., 2010, 182, 220-229.
53. Pandit, K.V.; Milosevic, J.; Kaminski, N. MicroRNAs in idiopathic pulmonary fibrosis. Transl. Res., 2011, 157, 191-199.
54. Yang, S.; Banerjee, S.; de Freitas, A.; Sanders, Y.Y.; Ding, Q.; Matalon, S.; Thannickal, V.J.; Abraham, E.; Liu, G. Participation of miR-200 in pulmonary fibrosis. Am. J. Pathol., 2011, 180, 484-493.
55. th March, 2013].
56. Janssen, H.L.; Reesink, H.W.; Zeuzum, S.; Lawitz, E.; Rodriguez-Torres, M.; Chen, A.; Davis, C.; King, B.; Levin, A.A.; Hodges, M.R. A randomized, double-blind, placebo-controlled safety and anti-viral proof-of-concept study of miraversen, an oligonucleotide targeting miR-122, in treatment naïve patients with genotype 1 chronic HCV infection. AASLD Annual Meeting Abstract LB-6; San Francisco, CA, 2011.